Ascentage Pharma Group International (ASPHF) Stock Price, News & Analysis

Company Overview

Ascentage Pharma Group International is a biopharmaceutical company focused on discovering and developing small-molecule therapies for cancer and other diseases involving abnormal cell survival. The company’s research programs target apoptosis, or programmed cell death, with the goal of restoring the body’s ability to eliminate cancer cells.

Its pipeline includes therapies directed at members of the BCL-2 protein family, inhibitors of inhibitor-of-apoptosis proteins (IAPs), and agents designed to reactivate the tumor-suppressor protein p53. Key programs have included lisaftoclax (APG-2575), a BCL-2 inhibitor being studied for hematologic malignancies, and APG-115, an MDM2-p53 antagonist under investigation in cancer indications. The company has also developed olverembatinib, a third-generation BCR-ABL tyrosine kinase inhibitor for certain patients with chronic myeloid leukemia.

Founded in 2009, Ascentage Pharma conducts research and development activities in China and the United States and serves patients through its oncology development and commercialization efforts. The company was co-founded and is led by Dr. Dajun Yang, who serves as chairman and chief executive officer. Its programs are evaluated through clinical studies and collaborations intended to address cancers with significant unmet treatment needs.

Key Stats

• Today's Range: $3.89 to $3.89
• 50-Day Range: $3.89 to $4.53
• 52-Week Range: $3.89 to $5.05
• Volume: N/A
• Average Volume: 325 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:ASPHF
• CIK: N/A
• Web: www.ascentage.cn
• Phone: 86-512-8555-7777
• Fax: N/A
• Employees: 767
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A